Status:
UNKNOWN
Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin Levels in Hyperandrogenic Lean Polycystic Ovarian Syndrome Women
Lead Sponsor:
Beni-Suef University
Collaborating Sponsors:
Cairo University
Conditions:
Polycystic Ovarian Syndrome
Eligibility:
FEMALE
20-30 years
Phase:
PHASE1
Brief Summary
High ucOC may favor insulin release in lean hyperandrogenic women to compensate for impaired insulin sensitivity. Meformin is an insulin sensitizing agent will be given for these women trying to inter...
Detailed Description
Under-carboxylated osteocalcin (ucOC), the precursor substrate of bone biomarker OC is a potent regulator of energy metabolism by promoting insulin production and adiponectin synthesis and decreasing ...
Eligibility Criteria
Inclusion
- Lean women BMI 25 or less
- Hyperandrogenic clinically and/or biochemically.
- Androgen Excess-Polycystic Ovary Syndrome (AE-PCOS) Society 2006 criteria
Exclusion
- BMI more than 20
- Other causes of hyperandrogenism
- Other causes of metabolic disorders or diabetes.
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02244567
Start Date
September 1 2014
End Date
June 1 2021
Last Update
February 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nesreen Abdel Fattah Abdullah Shehata
Cairo, Egypt